Leveraging Real-World and Passive Data to Significantly Improve Site Satisfaction and Reduce Trial Costs
In the rapidly evolving landscape of clinical trials, data collection remains one of the most time-consuming and cost-intensive processes. For decades, the manual abstraction of clinical data into electronic case report forms (eCRFs) has been the predominant method for gathering information from trial participants. This paradigm, largely unchanged since the 1990s, remains resource- intensive and[…]
› READ THE BLOGPOSTERS
Addressing Gaps in Real-World Data Sources through Automated Extraction of Psychiatric Comorbidities and Medication Side Effects from Clinical Notes
MAY 9, 2024
At ISPOR Annual 2024, Jessica Probst, MPH presented in the AI in HEOR poster tour on Addressing Gaps in Real-World Data Sources through Automated Extraction of Psychiatric Comorbidities and Medication Side Effects from Clinical Notes. This poster was also a Top 5% Finalist for the ISPOR 2024 Research Presentation Awards. View the full poster >>
Real-World Characterization and Management of Alopecia Areata Patients in the U.S.
MAY 16, 2023
View our poster on Real-World Characterization and Management of Alopecia Areata Patients in the U.S. Click to view!
EBOOKS
2024 Data Insights
DEC 18, 2024
In 2024, AI revolutionized drug development in the broader pharmaceutical landscape. Companies increasingly integrated AI to accelerate research, optimize clinical trials, and personalize patient care. This trend underscores the growing importance of AI-driven solutions in enhancing patient treatment efficiencies and outcomes. OM1 is at the forefront of this transformation – our award-winning, patented AI-powered digital phenotyping[…]
Real-World Analytics: A Complimentary Suite of Analytic Reports
JUL 15, 2024
A complimentary suite of analytic reports for understanding the reasons behind medication discontinuation, patient outcomes, and prescribing behaviors. Introduction to Real-World Analytics Reasons for Discontinuation Report Comparative Outcomes Report Prescriber Trends Report Meet our Experts View the ebook >>
VIDEOS
PhenOM: AI Solutions
JUL 16, 2024
PhenOM® is an artificial intelligence (AI)-powered digital phenotyping platform trained using OM1’s repository of linked EMR, claims and other data covering more than 300 million patients. The richness of the source data lets these phenotypes capture many complex facets of the target patients’ journeys. View the video on YouTube >>
OM1 Aspen: Integrated Evidence Generation
JUL 16, 2024
OM1 Aspen leverages our proprietary data sourcing, processing and enrichment technologies, including electronic medical records harmonization, image management, advanced medical text processing and linkage, to deliver a more efficient, cost-effective and scalable approach to research. Tap into our networks or build new ones for automated evidence generation. Harness scientifically robust data from large and diverse[…]
CASE STUDIES
Supporting Payer Adoption with Real-World Evidence: Nalu Medical Demonstrates Value with OM1 Data
OCT 6, 2025
Client Challenges Chronic peripheral nerve pain is debilitating, costly, and often unresponsive to conventional therapies. While Nalu Medical’s Peripheral Nerve Stimulation (PNS) System has shown strong clinical promise as a minimally invasive, drug-free approach to pain management, payer reimbursement of PNS therapies is limited by a lack of clear evidence demonstrating its economic value. To[…]
NEWS & ARTICLES
OM1 Rheumatoid Arthritis Dataset Rated High Quality as Cornerstone AI Partnership Speeds Future Quality Reviews
AUG 21, 2025
Read the full press release >> Aug 21, 2025 9:00 AM Eastern Daylight Time BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–OM1, a leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced that its Rheumatoid Arthritis (RA) specialty dataset achieved the highest quality score in an independent, AI-powered evaluation conducted by[…]
OM1 Adds a Half Million Patients to Neurology Network, Strengthening Real-World Evidence Generation and Accelerating Innovation in Neurology
AUG 12, 2025
Read the press release >> Aug 12, 2025 9:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–OM1, a leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced the expansion of its Neurology Specialty Network with the addition of 500,000 patients. The network now includes over 3 million individuals with electronic[…]
WHITE PAPERS
Standardized Library of Asthma Outcome Measures
APR 10, 2025
April 2019 Significant variation exists in both the types and definitions of outcome measures used in patient registries, even within the same clinical area. This variation reduces the utility of registries, making it difficult to compare, link, and aggregate data across the spectrum of clinical care and reporting. To address these limitations, the Agency for[…]
Standardized Library of Atrial Fibrillation Outcome Measures
APR 10, 2025
November 2018 Significant variation exists in both the types and definitions of outcome measures used in patient registries, even within the same clinical area. This variation reduces the utility of registries, making it difficult to compare, link, and aggregate data across the spectrum of clinical care and reporting. To address these limitations, the Agency for[…]
WEBINARS
From Promise to Reality: How AI Is Transforming Registries for Post-Approval Evidence Generation
OCT 16, 2025
Register >> Nov 13, 2025 11:00am ET Registries and other observational studies have long been seen as critical tools for generating post-approval real-world evidence—but traditional approaches have struggled to balance rigor, efficiency, and scalability. AI and automation are finally allowing registries to deliver on their long-held promise: capturing richer patient journeys, reducing burden, and enabling more[…]
Redefining Evidence Generation: Innovative AI-Enabled Approaches for a New Era of Therapies
OCT 16, 2025
Register >> November 7 @ 10:00 AM – 11:00 AM EST Medical Affairs is at the center of a shifting evidence landscape. As newly approved therapies and evolving standards of care bring urgent questions about safety, effectiveness, and utilization, traditional registries and clinical trials too often fall short—delivering answers that are delayed, incomplete, or unrepresentative. This webinar will explore how[…]